Abstract:The importance of astrocytes in neurodegenerative disorders, including Alzheimer's disease (AD), is well recognized. Yet, their exact role in the disease pathogenesis and progression remains unclear. Interestingly, human astrocytes have been found to be far larger and more complex than those of infraprimate mammals, making it necessary to concentrate research on diseased human astrocytes rather than animal cells. In this study, patient-specific induced pluripotent stem cells (iPSCs) were used as a source for human astrocytes. iPSCs were reprogrammed from skin fibroblasts of familial AD patients with deletion of exon 9 in the PSEN1gene (n=3) and from healthy age-matched controls (n=3). The deletion of exon 9 was corrected with CRISPR/Cas9 genome editing, enabling generation of isogenic control lines for the diseased lines. iPSCs were then further differentiated to GFAP and S100b-positive forebrain astrocytes according to our optimized protocol. iPSC-derived astrocytes are functional cells that are able to propagate calcium waves, uptake glucose, produce cytokines and glutathione, and release gliotransmitters, such as GABA and ATP. In addition, AD astrocytes show calcium leakage from ER and reduced presenilin endoproteolysis, both well-characterized defects linked to PSEN1mutations. Interestingly, inflammatory stimulation of AD astrocytes resulted in increased release of proinflammatory cytokines when compared to control cells. AD astrocytes also have alterations in mitochondrial mass, cellular metabolism and glutathione levels. Most importantly, astrocytes contribute to amyloid pathology and are able to both produce and uptake beta-amyloid. AD astrocytes secrete significantly higher amounts of the 1–42 form and show an elevated 1–42/1–40 ratio as compared to controls, but respond well to treatment with gamma-secretase inhibitor DAPT. Our data show that pathological findings commonly seen in AD patients are recapitulated in the iPSC-derived astrocytes. Thus, these cells offer a valuable tool for studying the disease mechanisms and for drug screening and testing novel therapeutic approaches in a cell-type specific manner.

Amyloid-β deposits in human astrocytes contain truncated and highly resistant proteoforms

Intracellular deposits of amyloid-beta influence the ability of human iPSC-derived astrocytes to support neuronal function

[P3–170]: HUMAN IPSC‐DERIVED ALZHEIMER's DISEASE ASTROCYTES RECAPITULATE DISEASE‐RELATED PHENOTYPES

Astrocytic accumulation of tau fibrils isolated from Alzheimer's disease brains induces inflammation, cell-to-cell propagation and neuronal impairment

The Difference in Gliosis Induced by Β-Amyloid and Tau Treatments in Astrocyte Cultures Derived from Senescence Accelerated and Normal Mouse Strains

Amyloid-β accumulation in human astrocytes induces mitochondrial disruption and changed energy metabolism

Astrocytic AT1R deficiency ameliorates Aβ-induced cognitive deficits and synaptotoxicity through β-arrestin2 signaling

Early Activation of Astrocytes Does Not Affect Amyloid Plaque Load in an Animal Model of Alzheimer’s Disease

Astrocytic uptake of posttranslationally modified amyloid‐β leads to endolysosomal system disruption and induction of pro‐inflammatory signaling

Monomeric and oligomeric amyloid-β cause distinct Alzheimer's disease pathophysiological characteristics in astrocytes in human glymphatics-on-chip models

Astrocytic GluN2A and GluN2B Oppose the Synaptotoxic Effects of Amyloid-β1-40 in Hippocampal Cells.

Alzheimer's disease-related amyloid-β induces synaptotoxicity in human iPS cell-derived neurons

Microglia-astrocyte interplay mitigates Aβ toxicity in a novel human 3D neurosphere model of Alzheimer's Disease

Reactive astrocytes acquire neuroprotective as well as deleterious signatures in response to Tau and Aß pathology

The effects of amyloid-β 42 oligomer on the proliferation and activation of astrocytes in vitro

Properties of Alzheimer’s disease brain-derived tau aggregates define tau processing by human astrocytes

Astrocytic proteins involved in regulation of the extracellular environment are increased in the Alzheimer's disease middle temporal gyrus

The Effects Of Amyloid-Beta(42) Oligomer On The Proliferation And Activation Of Astrocytes In Vitro

Contribution of glial cells to the development of amyloid plaques in Alzheimer’s disease

Glial alterations from early to late stages in a model of Alzheimer's disease: Evidence of autophagy involvement in Aβ internalization

Intraneuronal Abeta42 accumulation in human brain.